Efficacy of a novel rifamycin derivative, ABI-0043, against Staphylococcus aureus in an experimental model of foreign-body infection

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 7, 2007, Pages 2540-2545

  Trampuz, Andrej ^a   Murphy, Christopher K ^c   Rothstein, David M ^c   Widmer, Andreas F ^a   Landmann, Regine ^a   Zimmerli, Werner ^b,d  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b Kantonsspital Liestal   (Switzerland)

^c ActivBiotics Inc   (United States)

^d Medical University Clinic   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ABI 0043; RIFAMPICIN; RIFAMYCIN DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL COUNT; CONTROLLED STUDY; DEVICE INFECTION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SCREENING; EXPERIMENTAL INFECTION; FOREIGN BODY; GUINEA PIG; MALE; NONHUMAN; POLITEF IMPLANT; PRIORITY JOURNAL; SINGLE DRUG DOSE; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION;

ANIMALS; ANTI-BACTERIAL AGENTS; COLONY COUNT, MICROBIAL; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; FOREIGN-BODY REACTION; GUINEA PIGS; INJECTIONS, INTRAPERITONEAL; MALE; MICROBIAL SENSITIVITY TESTS; MOLECULAR STRUCTURE; OFLOXACIN; RIFAMPIN; RIFAMYCINS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TIME FACTORS;

EID: 34447250994     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00120-07     Document Type: Article

References (38)

1. Anderl, J. N., J. Zahller, F. Roe, and P. S. Stewart. 2003. Role of nutrient limitation and stationary-phase existence in Klebsiella pneumoniae biofilm resistance to ampicillin and ciprofloxacin. Antimicrob. Agents Chemother. 47:1251-1256.
2. Blaser, J., P. Vergeres, A. F. Widmer, and W. Zimmerli. 1995. In vivo verification of in vitro model of antibiotic treatment of device-related infection. Antimicrob. Agents Chemother. 39:1134-1139.
3. Brandt, C. M., W. W. Sistrunk, M. C. Duffy, A. D. Hanssen, J. M. Steckelberg, D. M. Ilstrup, and D. R. Osmon. 1997. Staphylococcus aureus prosthetic joint infection treated with debridement and prosthesis retention. Clin. Infect. Dis. 24:914-919.
4. Brause, B. D. 2005. Infections with prostheses in bones and joints, p. 1332-1337. In G. L. Mandell, J. E. Bennett, and R. Dolin (ed.), Principles and practice of infectious diseases. W.B. Saunders, Washington, DC.
5. Costerton, J. W., P. S. Stewart, and E. P. Greenberg. 1999. Bacterial biofilms: a common cause of persistent infections. Science 284:1318-1322.
6. Darouiche, R. O. 2001. Device-associated infections: a macroproblem that starts with microadherence. Clin. Infect. Dis. 33:1567-1572.
7. Donlan, R. M. 2001. Biofilms and device-associated infections. Emerg. Infect. Dis. 7:277-281.
8. Donlan, R. M. 2002. Biofilms: microbial life on surfaces. Emerg. Infect. Dis. 8:881-890.
9. Drancourt, M., A. Stein, J. N. Argenson, R. Roiron, P. Groulier, and D. Raoult. 1997. Oral treatment of Staphylococcus spp. infected orthopaedic implants with fusidic acid or ofloxacin in combination with rifampicin. J. Antimicrob. Chemother. 39:235-240.
10. Drancourt, M., A. Stein, J. N. Argenson, A. Zannier, G. Curvale, and D. Raoult. 1993. Oral rifampin plus ofloxacin for treatment of Staphylococcus-infected orthopedic implants. Antimicrob. Agents Chemother. 37:1214-1218.
11. Giulieri, S. G., P. Graber, P. E. Ochsner, and W. Zimmerli. 2004. Management of infection associated with total hip arthroplasty according to a treatment algorithm. Infection 32:222-228.
12. Laffer, R. R., P. Graber, P. E. Ochsner, and W. Zimmerli. 2006. Outcome of prosthetic knee-associated infection: evaluation of 40 consecutive episodes at a single centre. Clin. Microbiol. Infect. 12:433-439.
13. Murphy, C. K., S. Mullin, M. S. Osburne, J. van Duzer, J. Siedlecki, X. Yu, K. Kerstein, M. Cynamon, and D. M. Rothstein. 2006. In vitro activity of novel rifamycins against rifamycin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 50:827-834.
14. Murray, P. R., E. J. Baron, J. H. Jorgensen, M. A. Pfaller, and R. H. Yolken. 2003. Manual of clinical microbiology. American Society for Microbiology, Washington, DC.
15. National Committee for Clinical Laboratory Standards. 2003. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 7th ed. NCCLS document M7-A7. National Committee for Clinical Laboratory Standards, Wayne, PA.
16. Niemi, M., J. T. Backman, M. F. Fromm, P. J. Neuvonen, and K. T. Kivisto. 2003. Pharmacokinetic interactions with rifampicin: clinical relevance. Clin. Pharmacokinet. 42:819-850.
17. Rothstein, D. M., R. S. Farquhar, K. Sirokman, K. L. Sondergaard, C. Hazlett, A. A. Doye, J. K. Gwathmey, S. Mullin, J. van Duzer, and C. K. Murphy. 2006. Efficacy of novel rifamycin derivatives against rifamycin-sensitive and -resistant Staphylococcus aureus isolates in murine models of infection. Antimicrob. Agents Chemother. 50:3658-3664.
18. Rothstein, D. M., A. D. Hartman, M. H. Cynamon, and B. I. Eisenstein. 2003. Development potential of rifalazil. Expert Opin. Investig. Drugs 12: 255-271.
19. Rothstein, D. M., C. Shalish, C. K. Murphy, A. Sternlicht, and L. A. Campbell. 2006. Development potential of rifalazil and other benzoxazinorifamycins. Expert Opin. Investig. Drugs 15:603-623.
20. Sande, M. A. 1983. The use of rifampin in the treatment of nontuberculous infections: an overview. Rev. Infect. Dis. 5(Suppl. 3):S399-S401.
21. Schwank, S., Z. Rajacic, W. Zimmerli, and J. Blaser. 1998. Impact of bacterial biofilm formation on in vitro and in vivo activities of antibiotics. Antimicrob. Agents Chemother. 42:895-898.
22. Stamm, W. E., B. E. Batteiger, W. M. McCormack, P. A. Totten, A. Sternlicht, and N. M. Kivel for the Rifalazil Study Group. 8 February 2007, posting date. A randomized, double-blind study comparing single-dose rifalazil with single-dose azithromycin for the empirical treatment of nongonococcal urethritis in men. Sex. Transm. Dis. doi:10.1097/01.olg.0000253348.44308.8c.
23. Steckelberg, J. M., and D. R. Osmon. 2000. Prosthetic joint infection, p. 173-209. In A. L. Bisno and F. A. Waldvogel (ed.), Infections associated with indwelling medical devices. American Society for Microbiology, Washington, DC.
24. Stewart, P. S., and J. W. Costerton. 2001. Antibiotic resistance of bacteria in biofilms. Lancet 358:135-138.
25. Trampuz, A., D. R. Osmon, A. D. Hanssen, J. M. Steckelberg, and R. Patel. 2003. Molecular and antibiofilm approaches to prosthetic joint infection. Clin. Orthop. Relat. Res. 414:69-88.
26. Trampuz, A., and A. F. Widmer. 2006. Infections associated with orthopedic implants. Curr. Opin. Infect. Dis. 19:349-356.
27. Trebse, R., V. Pisot, and A. Trampuz. 2005. Treatment of infected retained implants. J. Bone Joint Surg. Br. 87B:249-256.
28. Widmer, A. F. 2001. New developments in diagnosis and treatment of infection in orthopedic implants. Clin. Infect. Dis. 33(Suppl. 2):S94-S106.
29. Widmer, A. F., R. Frei, Z. Rajacic, and W. Zimmerli. 1990. Correlation between in vivo and in vitro efficacy of antimicrobial agents against foreign body infections. J. Infect. Dis. 162:96-102.
30. Widmer, A. F., A. Gaechter, P. E. Ochsner, and W. Zimmerli. 1992. Antimicrobial treatment of orthopedic implant-related infections with rifampin combinations. Clin. Infect. Dis. 14:1251-1253.
31. Widmer, A. F., A. Wiestner, R. Frei, and W. Zimmerli. 1991. Killing of nongrowing and adherent Escherichia coli determines drug efficacy in device-related infections. Antimicrob. Agents Chemother. 35:741-746.
32. Zavasky, D. M., and M. A. Sande. 1998. Reconsideration of rifampin: a unique drug for a unique infection. JAMA 279:1575-1577.
33. Zimmerli, W. 1993. Experimental models in the investigation of device-related infections. J. Antimicrob. Chemother. 31(Suppl. D):97-102.
34. Zimmerli, W., R. Frei, A. F. Widmer, and Z. Rajacic. 1994. Microbiological tests to predict treatment outcome in experimental device-related infections due to Staphylococcus aureus. J. Antimicrob. Chemother. 33:959-967.
35. Zimmerli, W., P. D. Lew, and F. A. Waldvogel. 1984. Pathogenesis of foreign body infection: evidence for a local granulocyte defect. J. Clin. Investig. 73:1191-1200.
36. Zimmerli, W., A. Trampuz, and P. E. Ochsner. 2004. Prosthetic-joint infections. N. Engl. J. Med. 351:1645-1654.
37. Zimmerli, W., F. A. Waldvogel, P. Vaudaux, and U. E. Nydegger. 1982. Pathogenesis of foreign body infection: description and characteristics of an animal model. J. Infect. Dis. 146:487-497.
38. Zimmerli, W., A. F. Widmer, M. Blatter, R. Frei, P. E. Ochsner, et al. 1998. Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. JAMA 279:1537-1541.